The Certainty of a Post-Bone Marrow Diagnosis: A Study of the Yield of Bone Marrow Biopsies in a Community Hospital Setting

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 34-35
Author(s):  
Manasi M. Godbole ◽  
Peter A. Kouides

Introduction: Most studies on the diagnostic yield of bone marrow biopsy including the one by Hot et al. have focused on the yield of bone marrow biopsies in diagnosing the source of fever of unknown origin. However, there have not been any studies performed to our knowledge looking at overall practice patterns and yield of bone marrow biopsies for diagnoses other than fever of unknown origin. We aim to determine the most common indications for performing bone marrow biopsies in a community-based teaching hospital as well as the yield of the biopsies in patients with specified and unspecified pre-test indications to estimate the rate of uncertain post-test diagnoses. Methods: We performed a retrospective data collection study at Rochester General Hospital, NY. A comprehensive search was conducted in our electronic medical data to identify all patients who underwent bone marrow biopsies over a 5 year period from January 2011 - December 2016 for indications other than fever of unknown origin. Patient data including demographics, pre-bone marrow biopsy diagnosis and post-bone marrow diagnosis was obtained. All patients above the age of 18 who underwent bone marrow biopsy for indications other than fever of unknown origin or follow up treatment of a hematological malignancy were included. Results: A total of 223 biopsies were performed. The median age was 59 years (age range- 23-95). One hundred and sixteen patients were male and 107 were female. The most common indications for performing bone marrow biopsy were evaluation of the following possible conditions: multiple myeloma (n=54), myelodysplastic syndrome [MDS] (n=47), lymphoma (n=28) and leukemia (n=18) as well as non-specific indications such as pancytopenia (n=40), anemia (n=22) and thrombocytopenia (n=11). The proportion of cases confirmed by bone marrow biopsy was 45/54 (83%) with the pre-marrow diagnosis of multiple myeloma, 34/47 cases (72%) with the pre-marrow diagnosis of MDS, 15/18 (83%) with the pre-marrow diagnosis of leukemia and 13/28 (46%) in those with the pre-marrow diagnosis of rule out lymphoma. Thirteen cases (18%) with possible MDS had post-bone marrow diagnoses of leukemia, anemia of chronic disease, myelofibrosis or medication-related changes. Five out of twenty two cases (23%) for anemia and 3/11 cases (27%) for thrombocytopenia without otherwise specified pre-bone marrow etiology had uncertain diagnosis after bone marrow biopsy. Conclusion: In about a fifth of patients necessitating a bone marrow, the diagnosis is discordant and can be surprising. It is also worth reporting that in these discordant results, non-hematological causes such as medications, anemia due to chronic diseases or conditions such as cirrhosis or splenomegaly from other etiologies were among the final diagnoses. Interestingly, 20% of the patients with unspecified pre-bone marrow diagnoses such as anemia or thrombocytopenia in our study had an unclear post-bone marrow diagnosis despite undergoing bone marrow biopsy. Our findings are a reminder that the bone marrow exam does not always lead to a definitive diagnosis and the need by exclusion to include in the differential non-hematological etiologies such as nutritional deficiencies, chronic kidney disease or autoimmune disorders. Disclosures No relevant conflicts of interest to declare.

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 3996-3996
Author(s):  
Mohamed E Salama ◽  
Graham E. Wagner ◽  
Tamara Berno ◽  
Jessica Kohan ◽  
Fenghuang Zhan ◽  
...  

Abstract Abstract 3996 Background: Bone loss and related complications including bone pains, fractures and hypercalcemia are major causes of morbidity and mortality in multiple myeloma (MM) patients. Bone growth/loss (Bone mineral densitometry) can be monitored by dual x-ray absorptiometry (DXA) in patients with smoldering myeloma (SMM). We previously reported a novel quantitative method to asses trabecular volume (TV) using whole scanned slides and image analysis (WSI) obtained from bone marrow biopsy (Teman et al. 2010). This method provides a low cost reproducible mean to assess TV in archival paraffin embedded biopsy materials. Velcade has been shown to produce an anabolic bone effect in relapsed/refractory MM patients and in this study, we examine the effect of low-dose bortezomib (Velcade) in SMM patients using the WSI methodology. Methods: Bone marrow biopsy slides obtained before, during and after bortezomib treatment were used to evaluate TV. H&E stained core biopsy slides were scanned using Scan Scope XT system (Aperio Technologies, Vista, CA) into digital whole slide images that is viewable on Aperio Image Scope. We developed classifier algorithms using Genie (Aperio) pattern recognition image analysis software (PRIA) that were adept at identifying bone, hematopoietic tissue, and clear glass. The calculated bone area (TV) was represented as a ratio of the total hematopoietic area for each biopsy event. Slides were excluded if the analysis available area was less than 6mm2 or could not be classified correctly to the satisfaction of the pathologist Mixed-effects models were used to compare bone TV/hematopoietic ratios (HR) over time and between the different groups, as well as assess any correlation with that ratio and light chain, B-2-microglobulin, and plasma cell levels. Results were considered statistically significant if p<0.05. Results: Slides from 253 consecutive biopsies composed the study materials. 45 were excluded due to significant artifacts or small analysis areas (<6mm2). 208 bone marrow biopsies from 43 patients were included in the analysis. The group included 26 maintenance, 12 relapsed, and 5 smoldering patients; The relapsed and maintenance patients received Bortezomib alone or in combination for a minimum of three cycles; smoldering patients received bortezomib as part of a phase 2 study at the weekly dose of 0.7mg/kg. All maintenance and relapsed, patients had previously received bone marrow transplant with a median 68 years of age 29 were male. Median baseline TV/HR was 32.9%for maintenance 29.8% for relapse and 33.1% smoldering groups. A median increment of TV/RH (17%) was observed after Bortezomib treatment in all groups of patients (p<0.0001). Conclusion: Analysis of bone associated changes after Bortezomib exposure in patients with multiple myeloma by Scan Scope XT demonstrate a post treatment overall gain in bone formation. Monitoring bone indices in patients with multiple myeloma with PRIA may provide a valid tool to assess treatment associated bone effect. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 4840-4840
Author(s):  
Josy Mathew ◽  
Surbhi Shah ◽  
Virginia L. Kubic

Abstract Abstract 4840 Patients with hepatitis C often present with cytopenias - thrombocytopenia, neutropenia and less commonly anemia. Hypersplenism may contribute to cytopenias but effects on the bone marrow due to the hepatitis C infection also likely play a role in its pathogenesis. Hepatitis C infection predisposes to development of lymphomas as well. The bone marrow findings in patients with hepatitis C infection are not well described and to our knowledge there has only been one peer reviewed study published till date. In order to elucidate this further, we conducted a retrospective review of bone marrow biopsies performed at our institution on patients with known hepatitis C infection. Between years 1999 and 2010, 56 adults (36 male and 20 female) patient with hepatitis C underwent bone marrow biopsies. The indications for bone marrow biopsy included evaluation or staging of lymphoma or myeloma (24 patients) OR investigation of cytopenias (32 patients). None of the patients were on treatment for Hepatitis C at the time of the bone marrow biopsy. Of the 24 patients with lymphoma/myeloma, 11 showed bone marrow involvement, while 10 patients had benign lymphocyte aggregates in the marrow. 9 out of 24 patients had a hypercellular marrow and 8 had a hypocellular marrow. Mild to moderate megaloblastic change in the erythrocyte series was seen in 5 patients and dyserythropoiesis in 2. Hyperplasia of megakaryocytes was seen in 11/24 and 6/24 showed atypical megakaryocytes with focal clustering in 7/24. Reticulin fibrosis was noted in 7 patients. Iron stores were increased in 13/24 with decreased sideroblasts in 15/24 patients. Review of the 32 patients who had the bone marrow biopsy done for cytopenias showed 16 were hypocellular and 9 were hypercellular while 4 patients had variable cellularity. Mild to moderate megaloblastic change in the erythrocyte series was seen in 12/32 and dyserythropoiesis in 11/32. Granulocytic hypoplasia was seen in 14/32. Benign lymphoid aggregates were noted in 20 patients. Hyperplasia in the megakaryocytes was seen in 8 while 11 had decreased megakaryocytes. Atypical megakaryocytes were noted in 10/32 with clustering seen in 4 patients. Reticulin fibrosis was noted in 13 patients. Iron stores were increased in 16/32 and sideroblasts were decreased in 13/32. Frank hemophagocytosis was observed in 5 patients. Of these 32 patients, 4 were HIV positive. Myelodysplastic syndrome was diagnosed in 2/32, AML and Hemophagocytic lymphohistiocytosis in one each. Conclusions: Bone marrow biopsies are usually performed in patients with Hepatitis C to investigate cytopenias and for diagnosis or staging lymphoma or myeloma. Even without lymphoma involving the marrow, a substantial number of patients have benign lymphocyte infiltrates seen in the marrow. Marrow hypocellularity is common. Megaloblastic change in the erythroid series, dyserythropoiesis, atypical megakaryocytes and reticulin fibrosis can be seen in a substantial minority of the patients which contribute to cytopenias. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 5338-5338
Author(s):  
Finella MC Brito-Babapulle ◽  
Tanya Cranfield ◽  
Robert B Corser ◽  
Helen Dignum ◽  
Christopher James ◽  
...  

Abstract Mouse eosinophils have been shown in 2011 to be required for the maintenance of long lasting plasma cells in the bone marrow and in maintaining the bone marrow plasma cell microenvironment. Human eosinophils have been shown by Wong et al to support multiple myeloma cell proliferation via a mechanism independent of IL6. We looked at bone marrow biopsies taken from patients who had a paraprotein and in whom a diagnosis of multiple myeloma was suspected. These samples were taken solely for the purposes of diagnosisng multiple myeloma and were retrospectively reviewed from the point of view of degree of eosinophil infiltration and its correlation with tumour load, bone lytic lesions, plasma cell morphology, whether blastic, crystalline inclusions, Mott cells, flame cells and or lymphoplasmacytoid. There were no cases of IGD or E myeloma or osteosclerotic myeloma.Nonsecretory myeloma and cases of light chain myeloma with or without amyloid were included in the series. Biopsies were not performed from osteolytic lesion unless biopsy was necessary to make a diagnosis of myeloma. Myeloma was diagnosed when plasma cell infiltrate was greater than 10% on bone marrow aspirate with a paraprotein and or lytic lesions. Eosinophil infiltration did not correlate with any of the tumour clinicopathological markers but showed an inverse correlation with degree of plasmacytosis. Eosinophils were hardly ever found in marrow aspirates that had over 70% plasma cells. They were usually found in trephine sections of bone marrow in areas where there was Grade I/II fibrosis and were often found in close proximity to focal areas of plasma cell infiltration. Whether eosinophils play a role in preventing or maintaining malignant plasma cell recurrence is currently being studied. Disclosures: No relevant conflicts of interest to declare.


2003 ◽  
Vol 115 (7) ◽  
pp. 591-592 ◽  
Author(s):  
Shahid Ahmed ◽  
Anita K. Siddiqui ◽  
Bhoomi Mehrotra

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 5312-5312
Author(s):  
Qiguo Zhang ◽  
Hongyan Wu ◽  
Jian Ouyang ◽  
Bing Chen ◽  
Haibo Dong ◽  
...  

Abstract Objective To assess the argonaute 2 (Ago2) expression in the bone marrow of multiple myeloma (MM) and determine its association with angiogenesis. Methods Fifty-nine MM patients and sixteen normal controls were included. The bone marrow sections were made from plastic (methyl-methacrylate)- embedded bone marrow biopsies. The expression of Ago2 and CD34 in the bone marrow sections was detected by EnVison immunohistochemistry and the microvessel density (MVD) was then assessed. The bone marrow Ago2 expression level was also compared by western blot. The clinical significance of Ago2 expression and MVD in MM was analyzed. Results Western blot analysis indicated that the Ago2 expression was significantly increased in the bone marrow of MM patients as compared with normal controls. As assessed by immunohistochemistry, fifty MM patients were positive for Ago2 and nine patients were negative. However, sixteen normal controls were all negative for Ago2 (χ2=42.586,P<0.001). The β2-microglobulin levels were significantly higher in the Ago2 positive group as compared with the Ago2 negative group (Z=-2.014 , P=0.042). The MVD was significantly higher in bone marrow samples of MM patients compared to the normal controls (7.89±4.88 vs. 2.16±1.32, Z=-3.283 , P<0.001). Analysis of the correlation coefficients showed that Ago2 expression was positively associated with MVD in MM patients (r=0.461, P=0.023). MVD was also significantly higher in the Ago2 positive group than in the Ago2 negative group (Z=-2.449,P=0.014). Conclusion Ago2 expression was found to be significantly increased in the bone marrow of MM patients. Ago2 may take part in the pathogenesis of MM and mediate the angiogenesis. Disclosures No relevant conflicts of interest to declare.


2006 ◽  
Vol 61 (6) ◽  
pp. 363-366
Author(s):  
Philip R. Roelandt ◽  
Magda Dendooven ◽  
Kate De Groef ◽  
Antoon Van Couter

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 5126-5126
Author(s):  
Kimberley Ambler ◽  
Kevin W. Song ◽  
Larry Dian ◽  
Leslie Zypchen

Abstract Background: Monoclonal proteins (M-proteins) and osteoporosis are both common in the elderly. For most patients with M-proteins and osteoporosis, the protein represents monoclonal gammopathy of undetermined significance (MGUS). In rare cases, the M-protein signifies multiple myeloma, and the osteoporosis is secondary to myeloma bone disease. Thus, it is important to identify M-proteins in patients presenting with osteoporosis, and to consider whether such patients could have myeloma. Objectives: To determine the prevalence of M-proteins in patients age 65 and older referred to the Osteoporosis Clinic at BC Womens’ Hospital in Vancouver, BC, to review the management of patients with M-proteins, and to determine if the characteristics of patients with M-proteins differ from those without M-proteins. Methods: A retrospective chart review of patients age 65 and older referred to the Osteoporosis Clinic at BC Women’s Hospital from April 2006 – March 2008 was performed. Patient demographics, CBC, creatinine, calcium, serum protein electrophoresis, bone marrow biopsy results if available, bone density, presence of osteolytic lesions, fractures, and clinical diagnoses were recorded. Results: 224 charts were reviewed from 205 female and 19 male patients. Osteoporosis was diagnosed in 202 patients. 16 patients (7.1%) had an M-protein. The concentration of the M-protein ranged from &lt;1 g/L to 11 g/L. The characteristics of patients with and without M-proteins are presented in Table 1. Seven patients (3.1%) had background suppression of immunoglobulins with no detectable M-protein. Eight patients (50%) with M-protein had documented vertebral compression fractures compared to 70 patients (38%) with no M-protein. Five patients (31%) with and 41 patients (23%) without M-proteins had other fragility fractures. One patient with an M-protein had a mild anemia. All patients with M-proteins had normal calcium and creatinine. One patient with an M-protein was already known to have a B-cell lymphoma. Two patients were referred to a hematologist. One patient had a bone marrow biopsy and was diagnosed with multiple myeloma. No other patients were thought to have multiple myeloma, but no other bone marrow biopsies were performed. No extra investigations were done in the patients with hypogammaglobulinemia in the absence of an M-protein. Table 1. Characteristics of patients with and without M-proteins. Characteristic No M-Protein (n=201) M-Protein (n=16) Female (%) 184 (91) 14 (88) Age Mean ± SD 74 ± 7.7 77 ± 9.1 Osteoporosis (%) 182 (90) 15 (94) BD Mean ± SD −2.6 ± 1.2 −2.4 ± 1.5 Vertebral # (%) 70 (35) 8 (50) Fragility # (%) 41 (20) 5 (31) Conclusions: M-proteins are more common in elderly patients with osteoporosis than in the general population. Patients with osteoporosis and M-proteins may have an increased risk of fracture compared to such patients without M-proteins. In elderly patients with osteoporosis and M-proteins, it seems likely that the most common plasma cell dyscrasia is MGUS. However, the prevalence of multiple myeloma in these patients is unclear, and a standard approach to investigation is needed. While it is important not to miss a diagnosis of multiple myeloma, it is also prudent to avoid unnecessary invasive procedures (ie. bone marrow biopsies) in elderly and sometimes frail patients.


2004 ◽  
Vol 37 (5) ◽  
pp. 1599-1603 ◽  
Author(s):  
Edgardo S. Santos ◽  
Luis E. Raez ◽  
Paula Eckardt ◽  
Teresa DeCesare ◽  
Clarence C. Whitcomb ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document